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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is a major public health problem. Early diagnosis of MDR-TB
patients is essential for minimizing the risk of Mycobacterium tuberculosis (MTB) transmission. The conventional drug
susceptibility testing (DST) methods for detection of drug-resistant M.tuberculosis are laborious and cannot provide
the rapid detection for clinical practice.
Methods: The aim of this study was to develop a pyrosequencing approach for the simultaneous detection of
resistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (SM), ofloxacin (OFL) and amikacin
(AMK) in M. tuberculosis clinical isolates and sputum samples from re-treatment pulmonary tuberculosis (PTB)
patients. We identified the optimum conditions for detection mutation of rpoB, katG, rpsl, embB, gyrA and rrs gene
by pyrosequencing. Then this approach was applied to detect 205 clinical isolates and 24 sputum samples of
M. tuberculosis from re-treatment PTB patients.
Results: The mutations of rpoB and gyrA gene were detected by pyrosequencig with the SQA mode, and the
mutations of katG, rpsl, embB, gyrA and rrs gene were detected by pyrosequencing with SNP mode. Compared with
the Bactec MGIT 960 mycobacterial detection system, the accuracy of pyrosequencing for the detection of RIF, INH,
EMB, SM, AMK and OFL resistance in clinical isolates was 95.0%, 79.2%, 70.3%, 84.5%, 96.5% and 91.1%, respectively.
In sputum samples the accuracy was 83.3%, 83.3%, 60.9%, 83.3%, 87.5% and 91.7%, respectively.
Conclusions: The newly established pyrosequencing assay is a rapid and high-throughput method for the detection
of resistance to RIF, INH, SM, EMB, OFL and AMK in M.tuberculosis. Pyrosequencing can be used as a practical molecular
diagnostic tool for screening and predicting the resistance of re-treatment pulmonary tuberculosis patients.
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Background
The emergence and spread of MDR-TB and extensively
drug-resistant tuberculosis (XDR-TB) posed a severe im-
pediment for the prevention and control of tuberculosis
(TB) transmission [1-3]. According to the World Health
Organization (WHO) [4], there were about 650,000
cases of MDR-TB present in the world in 2010, and was
estimated that about 9% of these cases of XDR-TB. An-
nually, about 440,000 were infected with MDR-TB and
150,000 died of MDR-TB. Due to the severity of MDR-
TB, the WHO convened a international meeting focused
on MDR-TB in April 2009 in Beijing, China, urging
member states to take detailed and effective action in
diagnosing and treating M/XDR-TB [4]. Another survey
of WHO in 2010 showed that the estimated MDR-TB
among the notified re-treatment cases (n = 7,795) was
2,200 (28%) [5]. So the Global Plan to STOP TB (2006–
2015) proposed that by 2015 all countries should carry
out DST for all re-treatment tuberculosis patients [6]. In
order to control the MDR-TB,it was important for re-
treatment PTB patients to develop a rapid, reliable and
high-throughput drug susceptibility testing to obtain first-
and second-line anti-tuberculosis drugs susceptibility re-
sult simultaneously, as it was essential to decrease patient
morbidity and mortality as well as treatment-associated
costs.
At present, the conventional drug susceptibility test-
ing methods for M.tuberculosis were the bacterio-
logical methods performed by culture in liquid or on
solid media with highly sensitive and specific to most
anti-TB drugs. However, these methods were laborious,
time-consuming and could not provide rapid detection
for clinical practice. Consequently, the rapid molecular
diagnostic methods which performed within 1 or 2 days
would be helpful for shortening the detection time.
Spontaneous chromosomal mutations were the genetic
basis for drug resistance inM. tuberculosis [7,8]. At present,
RIF resistance was almost entirely associated with the mu-
tation of an 81-bp region of the rpoB gene, the RIF resist-
ance determining region (RRDR) [9-11]. The resistance to
INH, EMB, SM, OFL and AMK was primarily found in
mutations in the katG, embB, rpsl, gyrA and rrs genes,
respectively [8,12-16]. All these resistance-associated
mutations were predominantly found in a short region
or a position in M. tuberculosis genome and could be
considered as the beacons of molecular drug susceptibility
testing. Currently, the WHO endorsed some molecular
methods to detect individual anti-TB drugs susceptibility
by detecting gene mutations associated with drug re-
sistance, such as Xpert MTB/RIF [17] and GenoType
MTBDR [18] methods.
Pyrosequencing was a DNA sequencing technique that
was based on the detection of the pyrophosphate released
during DNA synthesis [19-21], and was well suitable for
large-scale screening for a short length DNA fragment. At
present, pyrosequencing had become a novel approach for
the detection of TB infection and tuberculosis resistance
[22-25]. Compared to GenoType MTBDR method, pyro-
sequencing was more accurate and easier to handle. Com-
pared to Xpert MTB/RIF method, pyrosequencing could
detect more drugs resistance. In this study, our aim was to
establish a rapid molecular method for the detection of tu-
berculosis resistance by pyrosequencing technology and to




The Shanghai Pulmonary Hospital Affiliated to Tongji
University School of Medicine Ethics Committee ap-
proved the research protocols (permit number: 2010–
034). The informed consent was obtained from each pa-
tient who was treated in accordance with the Helsinki
Declaration on the participation of human subjects in
medical research.
Source of clinical isolates and sputum samples
A total of 205 clinical M.tuberculosis isolates and 24 spu-
tum samples were obtained from PTB patients in Shang-
hai Pulmonary Hospital from January 2010 to March
2011. All the sputum specimens were smear-positive and
were classified according to an acid-fast bacillus (AFB)
staining scale as 1+ (1 case), 2+ (3 cases), 3+ (12 cases)
and 4+ (8 cases). All of the samples were identified as M.
tuberculosis by Bactec MGIT 960 culture, Ziehl-Neelsen
staining and standard biochemical identification testing
[26] and all of the samples were collected from re-
treatment PTB patients. The re-treatment PTB definition
was a patient who failed the standard initial tuberculosis
treatment regimen, who relapsed after initial treatment
with a standard or non-standard tuberculosis regimen. In
addition, 10 clinical isolates, including 3 isolates suscepti-
bility and 2 isolates resistant to RIF, INH, EMB, SM, AMK
and OFL and the other 5 isolates resistant to four or five
drugs, were collected from Shanghai Pulmonary Hospital.
These isolates were sequenced on an ABI 3730xl DNA
Analyzer by the Sangon Engineering Company (Shanghai,
China) to obtain the sequence of rpoB, katG, embB, rrs,
gyrA and rpsl genes. M.tuberculois standard strain
(H37Rv, ATCC25618) was purchased from the National
Culture Collection.
Specimen processing and genomic DNA extraction
For M.tuberculosis isolates, genomic DNA extraction was
performed as described previously [22]. For sputum sam-
ples, prior to DNA extraction, each sputum sample was
decontaminated with an equal volume of 2% NaOH and
0.5% NALC, incubated at room temperature for 20 min,
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neutralized with 67 mM phosphate buffer (pH 6.8) and
then centrifuged at 3,300 × g for 20 min at 4°C. The proc-
essed sediment was washed once using a sterile 0.9% NaCl
solution and re-suspended in 1.0 ml sterile 0.9% NaCl so-
lution. Two separate 500 μl aliquots were prepared in
1.5 ml tubes for the DNA extraction and Bactec MGIT
960 culture. The 500 μl aliquots for the DNA extraction
were inactivated and lysed for 30 min at 85°C and DNA
extraction was performed as described above for the ex-
traction of clinical isolates previously. The concentration
of the genomic DNA was measured by the Biophotometer
(Eppendorf).
Design of primers and PCR amplification
Regions of the rpoB, katG, embB, rrs, gyrA and rpsl genes
were amplified by conventional PCR. Amplification and
sequencing primers for pyrosequencing were designed with
PSQ assay design software (Biotage, Inc., Charlottesville,
VA). Primers and amplicon sizes were presented in Table 1.
Amplification reaction was performed in a final volume of
50 μl consisting of 0.5 μl 10 × PCR buffer, 0.2 mM deoxy-
nucleotide triphosphates (Takara), 1U Taq DNA polymer-
ase (Takara), 200 nM of each primer, and 10 ng of DNA.
Thermo-cycling conditions were as follows: 95°C for 3 min
followed by 50 cycles of 30 s at 95°C, 30 s at respective an-
nealing temperature, 30 s at 72°C and final elongation at
72°C for 10 min.
Protocols of pyrosequencing
Pyrosequencing was performed using PyroMark 96MA in-
strument (Qiagen, formerly Biotage AB, Inc.). PSQ 96MA
system had two modes to detect gene mutation. One was
dedicated sequence analysis (SQA) Software which could
give true sequence information about 50 bases. The other
was single-nucleotide polymorphism (SNP) Software which
could support fast genotyping results.
To determine the optimal mutation detection modes
for rpoB, katG, rpsl, embB, gyrA and rrs genes, 10
collected M.tuberculosis clinical isolates with known
sequence by Sanger Sequencing were detected gene mu-
tations by pyrosequencing with both SQA mode and
SNP mode. Then the results from pyrosequencing were
compared with the gold standard “Sanger sequencing”
results by the Identifire software. The pyrosequencing
results were considered valid if the pyrosequencing re-
sults were consistent with Sanger Sequencing results.
The detection mode and the nucleotide dispensation
order of pyrosequencing were considered optimum if
pyrosequencing results were valid and the assay could
consume less detection time and reagent. The conditions
were presented in Table 2.
The gene mutations of 205M.tuberculosis clinical iso-
lates and 24 sputum samples were detected by pyrose-
quencing under the optimal conditions as considered
above.
Table 1 Primers and thermo-cycling conditions of the pyrosequencing assays
Drug Gene Primer Sequences (5’—3’) Annealing temperature (°C) Size (bp) Target loci




INH katG Forward AGATGGGCTTGGGCTGGA 61 133 315
Reverse* TAGCCGTACAGGATCTCGAGGA
Sequencing CCGGTAAGGACGCGA
SM rpsl Forward* CAAGGGTCGTCGGGACAAGA 61 299
Reverse TCTTGACACCCTGCGTATCC
Sequencing 1 CGCCGAGTTCGGCTT 43
Sequencing 2 CACACCAGGCAGGTC 88
EMB embB Forward ACGACGGCTACATCCTGG 61 110 306
Reverse* GTTGTAATACCAGCCGAAGGGA
Sequencing CGACGGCTACATCCTG
OFL gyrA Forward TTCGATTCCGGCTTCCGCCC 61 192 QRDR
Reverse* TGGGTCATTGCCTGGCGAGC
Sequencing TACCACCCGCACGGC
AMK rrs Forward TCCTTAAAAGCCGGTCTCAGTTC 61 239 1401
Reverse* TCCGGTACGGCTACCTTGTTA
Sequencing CTTGTACACACCGCC
*: The primer was labeled at the 5-end with biotin.
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In brief, pyrosequencing method included preparation
of the template and sequencing reaction. Firstly the PCR
amplification product immobilized on the streptavidin-
coated sepharose beads (GE Healthcare, Uppsala, Sweden)
was converted into single-stranded DNA template and
purified with a vacuum preparation tool. Then a sequen-
cing primer was subsequently annealed to the template.
Pyrosequencing was performed in an automated Pyro-
Mark 96MA instrument according to the manufacturer’s
instructions. For the SQA mode detection, a PyroMark
Gold Q96 SQA reagents (Qiagen, 972812) and cyclic
dispensation of the nucleotide was used. The resultant
sequences were compared with a database containing
sequences of known mutations by mean of the Identifire
software. The mutation types and loci were determined
using alignment with the sequence results of M.tuberculosis
H37Rv (ATCC25618, and GenBank accession no.
NC_000962) [27]. For the SNP mode, the genotyping
results were directly obtained by using the PyroMark
Gold Q96 reagents (Qiagen, 972804). During pyrose-
quencing testing, amplified H37Rv genomic DNA was
employed as a control. Some new nucleotide sequences
were submitted to the Genbank (Accession numbers:
KJ659894, KJ659895, KJ659896, KJ659897, KJ659898,
KJ659899, KJ659900, KJ659901, KJ659902).
DST of M.tuberculosis by the Bactec MGIT 960 system
DST was performed using the Bactec MGIT 960 myco-
bacterial detection system. Drug concentrations used in
the MGIT 960 system were: RIF: 1.0 μg/ml, INH: 0.1 μg/
ml, SM: 1.0 μg/ml, EMB: 5.0 μg/ml, OFL: 2.0 μg/ml and
AMK: 1.0 μg/ml [28].
Statistical analysis
Data analysis was carried out using Stata version 9 (Sta-
tacorp, Texas, USA). The sensitivity, specificity and ac-
curacy were calculated for pyrosequencing results versus
Bactec MGIT 960 system results. The Bactec MGIT 960
system results were considered as the gold standard of
DST for comparison with the results obtained from py-
rosequencing. The agreement between the pyrosequenc-
ing results and Bactec MGIT 960 results was analyzed
using Kappa value.
Results
DST using Bactec MGIT 960 system
DST of RIF, INH, SM, EMB, OFL and AMK was
detected by Bactec MGIT 960 system. Of the 229 re-
treatment PTB patients samples, 89.5% cases were iden-
tified resistant to at least one of the tested drugs, above
50% cases were resistant to four or five tested drugs and
6.6% cases were resistant to only one drug.
Pyrosequencing results for the detection of gene
mutations
All of the 205 clinical isolates and 24 sputum samples,
pyrosequencing identified 10 kinds of codon involving in
39 types of mutations in RRDP of the rpoB gene, and
60.4% (110/182) and 20.3% (37/182) of the RIF-resistant
clinical samples had a mutation at the codon 531 and
526, respectively, in Table 3. The 74.2% (141/190) of the
INH-resistant clinical samples had a mutation at codon
315 in the katG gene. No mutation in katG S315 was
found in INH-susceptible clinical samples. The 65.4%
(100/153) and 11.8% (18/153) of the SM-resistant clin-
ical samples had a mutation at the codon 43 and 88, re-
spectively, in the rpsl gene. The 55.5% (76/137) of the
EMB-resistant clinical samples had a mutation at codon
306 in the embB gene. There were four kinds of codons
including 12 types of mutations in the regions of the
quinolone resistance-determining regions (QRDR) of the
gyrA gene, and 62% (88/142) of the OFL-resistant clin-
ical samples had a mutation at codon 94. The 77.3% (34/
44) of the AMK-resistant clinical samples showed a mu-
tation in position 1401 in the rrs gene, and no mutation
in this position was found in AMK-susceptible clinical
samples. Mutations of the katG, embB, rrs, gyrA and rpsl
genes were identified by pyrosequencing shown in Table 4.
The detailed information of sequences were provided in
the Additional file 1
The performance of pyrosequencing for the detection of
TB resistance
Compared with Bactec MGIT 960 method, pyrosequenc-
ing showed higher sensitivity and specificity in RIF, OFL,
AMK and SM than in INH and EMB. The detection of
EMB resistance showed the lowest sensitivity among six
drugs not only in clinical isolates (58.7%) but also in
Table 2 Optimum conditions for detection mutation of rpoB, katG, gyrA, rrs, embB and rpsl genes by pyrosequencing
Loci Detection mode Nucleotide dispensation order
rpoB SQA mode RRDR mutation: 16(AGCT)
katG SNP mode 315 mutation: GTCACAGTCTG
rpsl SNP mode 43 mutation: CGATACGAGT88 mutation: CGATGCACGC
embB SNP mode 306 mutation:TGCAGTGACGCGCAGT
gyrA SQA mode QRDR mutation: 12(GACT)
rrs SNP mode 1401 mutation: TCGTCAGTCAGTCAT
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sputum samples (41.7%). The INH and AMK showed the
highest specificity (100%) in all the detecting drugs and
samples. These results were present in Table 5.
Discussion
In this study, we developed a method for detecting RIF,
INH, EMB, SM, OFL and AMK resistance by the pyro-
sequencing technology and evaluated this method on a
panel of 229 clinical samples of M.tuberculosis. We opti-
mized the pyrosequencing conditions to detect drug re-
sistance to six anti-TB drugs. In the pyrosequencing
operating system,two modes, SQA and SNP, could be
used, but the two modes differed in several aspects. For
example, SQA mode detected a short and medium
length DNA fragment, and SNP mode detected only a
single base variation. In our experiments, although SQA
mode could detect all 6 drugs resistance, we chose the
SNP mode rather than SQA mode to detect the mu-
tation of katG, rpsl, embB and rrs based on the below
reasons. The mutations of these genes were mainly in-
volved a few point mutations. In detection resistance of
INH, only katG gene at codon 315 was detected; in
EMB, only embB gene at codon 306 was detected; in
SM, only rpsl gene at codon 44 and 88 was detected; in
AMK, only rrs gene at nucleotide position 1401 was de-
tected. However, for rpoB and gyrA gene, we chose the
SQA mode to detect the mutation because the sequence
of interesting had been highly polymorphic and a short
region should be sequenced. The most important advan-
tage for choosing the SNP mode rather than SQA mode
was that the former was quicker than the latter. By SNP
mode, it was possible to sequence 96 samples in ap-
proximately 15 min, while it needed 70 min by the SQA
mode. Thus, the time needed by SNP mode was shorter
approximately only one- fourth of the time needed by
SQA mode. Another advantage with SNP mode over
SQA mode was that it could greatly reduce the detection
cost to be 1/3.
The traditional gold standard for detection drug resist-
ance of tuberculosis was the bacteriological methods.
Therefore, we compared the results of pyrosequencing
with the Bactec MGIT 960 mycobacterial detection sys-
tem. The pyrosequencing approach showed different
sensitivity and specificity among six drugs. For clinical
isolates, the sensitivity of pyrosequencing for detecting
resistance to the six drugs ranged from 58.7% to 94.4%,
and the specificity was above 87.7%.
In RIF assay, compared to Bactec MGIT 960 DST, the
sensitivity and specificity of the pyrosequencing method
were similar to previously reported values [29]. The 95.0%
(192/202) of pyrosequencing results were concordant with
the results of Bactec MGIT 960. Among the ten inconsist-
ent specimens, one isolate which was RIF susceptible was
resistant by prosequecing and the mutation was detected
Table 3 Mutations of the rpoB gene identified by
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Q510H + H526Y CAG/CAC + CAC/TAC 1
L511P + D516G CTG/CCG + GAC/GGC 1
L511P + Q513P CTG/CCG + CAA/CCA 1
L511P + D516G +
N518S
CTG/CCG + GAC/GGC +
AAC/GAC
1
N518S + H526P AAC/AGC + CAC/CCC 1
S512T + D516G AGC/ACG + GAC/GGC 1
D516A + L533P GAC/GCC + CTG/CCG 1
H526N + L533P CAC/AAC + CTG/CCG 1
H526Q + L533P CAC/CAG + CTG/CCG 1
H526Y + S531T +
L530R
CAC/TAC + TCG/ACG +
CTG/CGT
1
L511P + S531L CTG/CCG + TCG/TTG 1
D516A + S531L GAC/GCC + TCG/TTG 1
D516V + S531L GAC/GTC + TCG/TTG 1
S531L + L533R TCG/TTG + CTG/CGG 1
H526D + L533R CAC/GAC + CTG/CGG 1
H526Y + L533R CAC/TAC + CTG/CGG 1
S531L + L533S TCG/TTG + CTG/TCG 2
WT 12 45
Fail 3
R: resistance; S: susceptibility; WT: wild type.
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at codon Leu 511 Pro. This mutation usually occurred in
RIF resistant isolates together with other mutations [29];
therefore this mutation alone maybe had low predictive
value for RIF resistance. The other nine phenotypical RIF
resistant isolates did not detect a mutation in the RRDR
and it was possible that another mutations existed outside
the RRDR or elsewhere in the genome.
In INH assay, the specificity was high to be 100%,
whereas the sensitivity of detecting resistance to INH
was much low. The relatively low sensitivity in the de-
tection of INH resistance might be related to only katG
315 detected. Both inhA and aphC had also been dem-
onstrated to confer the INH resistance [14,30]. So these
genes might increase the sensitivity when evaluated.
In SM assay, the codon 43 and 88 of rpsl gene were
detected by pyrosequencing and showed low sensitivity.
In previous report, the mutations in position 513 or 516
of rrs gene were correctly identified in SM-resistant clin-
ical isolates [31]. Therefore, the sensitivity might in-
crease when these genes involved.
The sensitivity and specificity of detection of EMB re-
sistance were the lowest among six drugs, which were
consistent with the previous study [32]. These results
also suggested that codon 306 point mutation in the
embB gene was a poor indicator of EMB resistance, and
other genes, such as embC and embA might confer EMB
resistance [33].
The high specificity of the OFL assay (98.7%) and the
low sensitivity (86.4%) were analyzed here. One OFL-
susceptible isolates was identified as resistant by the py-
rosequencing assay because the MIC (0.5 μg/ml) for this
isolate was close to the critical concentration for OFL
(1.0 μg/ml). The other 17 of the 125 phenotypical OFL-
resistant isolates did not detect a mutation in the QRDR
of the gyrA gene, which might have other mutation
existed other site in gyrA or in gyrB gene [34].
The specificity of AMK resistance was 100%, and the
sensitivity was low (82.1%). The 7 of the 39 AMK-resistant
isolates without a mutation at position 1401 in the rrs
gene suggested that another mutation might exist in other
site of rrs gene or other genes conferring AMK resistance.
These results might provide the cues to further studies on
AMK resistance.
In addition, we detected the resistance of 24 smear-
positive sputum samples by pyrosequencing in re-treatment
PTB patients, which showed that pyrosequencing ap-
proach could applied to detect smear-positive sputum
specimens. Then the bacterial culture avoided by this
direct examination of sputum samples, and the detect-
ing turn-around time could greatly shorten. However,
most of the samples in our study were quantified as 3+
to 4+ for acid-fast (AFB) staining, so this application
could be used to study in large scale and in sputum spe-
cimen of 1+ or 2+ acid-fast (AFB) staining. The nested
Table 4 Mutations of the katG, embB, rrs, gyrA and rpsl
genes identified by pyrosequencing in clinical isolates
and sputum samples
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M306I ATG/ATA 17 4
M306I ATG/ATC 2 2
M306I ATG/CTG 7 2
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PCR might be essential when detected the sputum spec-
imens with 1+ or 2 + .
Conclusions
We concluded that the pyrosequencing is a rapid and
high-throughput method for the detection of resistance to
RIF, INH, SM, EMB, OFL and AMK in M.tuberculosis. Py-
rosequencing can be used as a practical molecular diag-
nostic tool for screening and predicting the resistance for
re-treatment pulmonary tuberculosis patients.
Additional file
Additional file 1: The detailed information of sequences in this
study.
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